Logo

DMAC

DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc. • NASDAQ
$8.63 ▼ -5.37% (-0.49)
Market Cap $449.43 M
52w High $9.23
52w Low $3.19
Dividend Yield 0%
P/E -12.15
Volume 239.88K
Outstanding Shares 52.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $9.015M ▲ $-8.62M ▼ 0% $-0.17 ▲ $-8.596M ▼
Q2-2025 $0 $8.007M ▼ $-7.699M ▲ 0% $-0.18 $-8.004M ▲
Q1-2025 $0 $8.144M ▼ $-7.707M ▲ 0% $-0.18 $-8.133M ▼
Q4-2024 $0 $8.408M ▲ $-7.9M ▼ 0% $-0.18 ▼ $-7.88M ▼
Q3-2024 $0 $6.883M $-6.274M 0% $-0.15 $-6.873M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $55.318M ▲ $57.047M ▲ $5.425M ▲ $51.622M ▲
Q2-2025 $30.038M ▼ $31.47M ▼ $4.3M ▼ $27.17M ▼
Q1-2025 $36.32M ▼ $38.83M ▼ $4.876M ▼ $33.954M ▼
Q4-2024 $44.147M ▼ $46.345M ▼ $5.627M ▲ $40.718M ▼
Q3-2024 $50.197M $52.524M $4.56M $47.964M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.62M ▼ $-6.605M ▲ $-26.205M ▼ $32.012M ▲ $-783K ▼ $-6.621M ▲
Q2-2025 $-7.699M ▲ $-7.598M ▼ $8.957M ▲ $161K ▲ $1.52M ▲ $-7.604M ▼
Q1-2025 $-7.707M ▲ $-7.149M ▼ $6.622M ▲ $91K ▼ $-436K ▲ $-7.161M ▼
Q4-2024 $-7.9M ▼ $-6.434M ▼ $5.205M ▲ $120K ▼ $-1.109M ▲ $-6.441M ▼
Q3-2024 $-6.274M $-4.47M $-5.585M $123K $-9.932M $-4.479M

Five-Year Company Overview

Income Statement

Income Statement DiaMedica is still a pure research-stage biotech, so it has essentially no product revenue yet. All spending is going into development, which shows up as steady operating losses year after year. The losses have been relatively small and fairly consistent, suggesting controlled spending but also a full dependence on external funding until a partnership or commercial product emerges. Earnings per share remain negative, which is normal at this stage but underlines that the business is not yet economically self-sustaining.

Balance Sheet

Balance Sheet The balance sheet is lean and simple. The company holds a modest asset base, mostly in cash and equivalents, with no reported financial debt, which reduces financial risk. Shareholders’ equity is positive, meaning assets still comfortably exceed liabilities, but the overall scale of the balance sheet is small, typical of a clinical-stage biotech. This structure gives some financial flexibility but also highlights that future progress will likely rely on new capital raises or partnerships rather than internal cash generation.

Cash Flow

Cash Flow Cash flows reflect a classic early-stage biotech profile: money flows out steadily to fund research and clinical trials, with no offsetting inflows from product sales. Operating cash burn has been consistent and moderate, and capital spending is minimal, so nearly all cash use is tied directly to advancing the drug pipeline. This is efficient in the sense that little is spent on fixed assets, but it also means the company must plan carefully around trial milestones and future financing to avoid cash shortfalls.

Competitive Edge

Competitive Edge DiaMedica’s competitive position rests on specialization rather than size. The company is focused on one lead drug, DM199, aimed at serious ischemic conditions like preeclampsia and stroke, where treatment options are very limited. It benefits from strong patent protection, proprietary manufacturing know-how, and a head start in preeclampsia, where there are no approved therapies today. However, its small scale and single-asset dependence also make it vulnerable to setbacks in that program or to larger competitors entering once the space is validated.

Innovation and R&D

Innovation and R&D Innovation is the core of the DiaMedica story. DM199 is a recombinant version of a natural protein that helps regulate blood flow, with a mechanism designed to restore the body’s own protective pathways rather than just manage symptoms. The company is testing this in difficult, high-need areas such as preeclampsia, fetal growth restriction, and acute ischemic stroke, including exploring a longer treatment window in stroke than current standards allow. R&D efforts are highly concentrated, which can accelerate learning around DM199 but also means the overall pipeline is not diversified if trials disappoint. Key upcoming trial readouts over the next few years will be crucial in determining whether this innovation translates into real medical and commercial impact.

Summary

DiaMedica is a small, clinical-stage biotech built around a single, potentially first-in-class therapy with a novel mechanism and strong patent protection. Financially, it operates with no product revenue, modest but persistent losses, and steady cash burn, funded by its balance sheet rather than by operations. The absence of debt and focused use of cash are positives, but long-term success depends on securing future funding and, most importantly, on favorable clinical and regulatory outcomes. If its lead program succeeds, the company is positioned in large, underserved markets; if it fails, there is limited backup within the current pipeline. Overall, this is a high-risk, innovation-driven profile typical of early-stage biotechnology companies, where upcoming trial milestones are the main drivers of future prospects.

NEWS

November 12, 2025 · 4:30 PM UTC

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Read more

November 10, 2025 · 8:15 AM UTC

DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Read more

November 6, 2025 · 4:15 PM UTC

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

Read more

September 29, 2025 · 4:15 PM UTC

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Read more